<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02935023</url>
  </required_header>
  <id_info>
    <org_study_id>SPHIC-TR-PCa2016-01</org_study_id>
    <nct_id>NCT02935023</nct_id>
  </id_info>
  <brief_title>Carbon Ion Radiotherapy in Treating Patients Undergoing Systemic Therapy for Oligo-metastatic Prostate Cancer</brief_title>
  <official_title>Carbon Ion Radiotherapy in Treating Patients Undergoing Systemic Therapy for Oligo-metastatic Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Proton and Heavy Ion Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Proton and Heavy Ion Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical study is to determine impact of carbon ion radiotherapy (CIRT)
      treatment in combination with systemic therapy for oligo-metastatic prostate cancer. The
      primary objective: to determine disease biochemical progression-free survival in man with
      oligo-metastatic (M1a/b) prostate cancer undergoing systemic therapy with definitive
      radiotherapy of the primary tumor. The secondary objective: to determine local control,
      overall survival and quality of life in men with oligo-metastatic prostate cancer undergoing
      carbon ion radiotherapy
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to PSA relapse</measure>
    <time_frame>From the start of systemic therapy, a median of 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>From the start of systemic therapy, a median of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From the start of systemic therapy, a median of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>From the start of carbon ion radiotherapy, a median of 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">47</enrollment>
  <condition>Metastatic Prostate Carcinoma</condition>
  <arm_group>
    <arm_group_label>CIRT with systemic therapy arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carbon ion radiotherapy combined with systemic therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>CIRT with systemic therapy arm</intervention_name>
    <description>carbon ion radiotherapy to the prostate(59.2GyE/16Fx to prostate and seminal vesicle) Systemic therapy:Hormonal therapy (LHRH agonist and/or antiandrogens) or chemotherapy</description>
    <arm_group_label>CIRT with systemic therapy arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pathologically confirmed adenocarcinoma of the prostate

          2. Age ≥ 20 and &lt; 80 years of age

          3. ECOG PS 0 or 1

          4. Life-expectancy ≥1 year

          5. Stage T1-4,N0-1,M1a/b disease on imaging, with a combined maximum of 3 synchronous
             lesions.

          6. Ability to understand and willingness to sign informed consent

        Exclusion Criteria:

          1. No pathologically confirmed adenocarcinoma of the prostate

          2. visceral metastasis

          3. Previous pelvic radiotherapy or prostatectomy

          4. Severe systemic disorders
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shen Fu, PhD.MD.</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai Proton and Heavy Ion Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ping Li, MD.</last_name>
    <phone>+86 02138296666</phone>
    <email>ping.li@sphic.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qing Zhang, MD.</last_name>
    <phone>+86 02138296666</phone>
    <email>qing.zhang@sphic.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Proton and Heavy Ion Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201321</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renli Ning</last_name>
      <phone>+86 02138296666</phone>
      <email>renli.ning@sphic.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2016</study_first_submitted>
  <study_first_submitted_qc>October 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2016</study_first_posted>
  <last_update_submitted>October 13, 2016</last_update_submitted>
  <last_update_submitted_qc>October 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Proton and Heavy Ion Center</investigator_affiliation>
    <investigator_full_name>Shen Fu</investigator_full_name>
    <investigator_title>Director,department of radiation oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

